MedPath

Tradjenta

These highlights do not include all the information needed to use TRADJENTA safely and effectively. See full prescribing information for TRADJENTA. TRADJENTA (linagliptin tablets), for oral useInitial U.S. Approval: 2011

Approved
Approval ID

b1da67d4-51e0-41b7-9fe1-7f38c0d1baa1

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 22, 2024

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

linagliptin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50090-4383
Application NumberNDA201280
Product Classification
M
Marketing Category
C73594
G
Generic Name
linagliptin
Product Specifications
Route of AdministrationORAL
Effective DateJune 26, 2023
FDA Product Classification

INGREDIENTS (1)

LINAGLIPTINActive
Quantity: 5 mg in 1 1
Code: 3X29ZEJ4R2
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tradjenta - FDA Drug Approval Details